Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.38 EUR
Change Today +0.003 / 0.79%
Volume 0.0
4HW On Other Exchanges
As of 11:19 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

molecular medicine spa (4HW) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - €0.47
52 Week Low
01/12/15 - €0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MOLECULAR MEDICINE SPA (4HW)

Related News

No related news articles were found.

molecular medicine spa (4HW) Related Businessweek News

No Related Businessweek News Found

molecular medicine spa (4HW) Details

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in a Phase III trial in acute leukaemia patients in first or subsequent complete remission and at high risk of relapse, suitable for haploidentical haematopoietic stem cell transplantation. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has agreements with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.

Founded in 1996

molecular medicine spa (4HW) Top Compensated Officers

Founder, Chairman, Chairman of the Scientific...
Total Annual Compensation: €750.0K
Business Development & IR Director, General M...
Total Annual Compensation: €409.0K
Director of Business Development & Strategic ...
Total Annual Compensation: €406.0K
Compensation as of Fiscal Year 2014.

molecular medicine spa (4HW) Key Developments

MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2015

MolMed S.p.A. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total operating revenues of EUR 2,658,000 against EUR 1,405,000 a year ago. Operating loss was EUR 4,141,000 against EUR 5,159,000 a year ago. Pre-tax loss was EUR 4,232,000 against EUR 5,199,000 a year ago. Loss for the period was EUR 4,232,000 against EUR 5,199,000 a year ago. The increase in revenues is mainly due to the intensification of GMP development and production activities for third parties.

MolMed S.p.A. Presents at BioEquity Europe 2015, May-20-2015 09:20 AM

MolMed S.p.A. Presents at BioEquity Europe 2015, May-20-2015 09:20 AM. Venue: InterContinental Vienna, Vienna, Austria.

MolMed S.p.A. Reports Earnings Results for the Year Ended December 31, 2014

MolMed S.p.A. reported earnings results for the year ended December 31, 2014. Total operating revenues in 2014, equal to EUR 12.4 million, show a marked increase of 85.0% compared to EUR 6.7 million reported in the year 2013, mainly due to the intensification of development and GMP production activities for third parties. The operating loss for 2014 amounts to EUR 12.6 million, shows a 29.5% improvement with respect to year 2013, which recorded a loss of EUR 17.9 million. Pre-tax loss was EUR 13.0 million against EUR 18.2 million reported last year. The result of year 2014 shows a loss of EUR 13.0 million, compared to a loss of EUR 18.2 million recorded for the year 2013. Total cash absorbed by operating activities was EUR 6.2 million against EUR 13.9 million reported last year. Net investment in tangible assets was EUR 4.6 million against EUR 1 million reported last year. Net investment in intangible assets was EUR 0.1 million against EUR 0.04 million reported last year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4HW:GR €0.38 EUR +0.003

4HW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4HW.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4HW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOLECULAR MEDICINE SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at